# US 2026/0022357 A1 · Recombinant proteins for gene delivery and insertion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0022357 A1
- Document ID: US20260022357A1
- Status: Published application
- Kind: A1
- Application number: 19/224,551
- Filed: 2025-05-30
- Published: 2026-01-22
- Earliest claimed: 2022-12-02
- Applicants: Averna Therapeutics Ltd
- Inventors: Yaron BEN SHUSHAN-GOLECZKI; Noga KOWALSMAN; Devin TRUDEAU
- Web page: https://patentgrep.com/patent/US20260022357A1

## CPC

- C12N 9/22: Ribonucleases {[RNase]; Deoxyribonucleases [DNase]}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C07K 14/195: from bacteria
- C07K 14/4702: {Regulators; Modulating activity}
- C12N 9/1252: {DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase}
- C12N 9/1276: {RNA-directed DNA polymerase (2.7.7.49), i.e. reverse transcriptase or telomerase}
- C12N 15/85: for animal cells
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- C07K 2319/09: containing a nuclear localisation signal
- C07K 2319/80: containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N 2800/90: Vectors containing a transposable element
- C12Y 207/07007: DNA-directed DNA polymerase (2.7.7.7), i.e. DNA replicase
- C12Y 207/07049: RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
- C12Y 207/13003: Histidine kinase (2.7.13.3)
- C12Y 301/26004: Ribonuclease H (3.1.26.4)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

The present disclosure provides compositions and methods for delivering a gene of interest to a subject. Aspects of the application relate to nucleic acids encoding modified retroelement-derived polypeptides and gene delivery constructs that can direct integration of a nucleic acid sequence into a target nucleic acid (e.g., a genome of a subject).

## Claims

### Claim 1

A nucleic acid encoding an engineered protein comprising a retroelement-derived polypeptide and at least one heterologous polypeptide-;
wherein the retroelement-derived polypeptide is derived from a non-long terminal repeat (non-LTR) retrotransposon, wherein the non-LTR retrotransposon is an apurinic/apyrimidinic endonucleases (APE)-type retrotransposon selected from a ZFL2-2 retrotransposon, a Vingi-1_Acar retrotransposon, a Vingi-2_Acar retrotransposon, a L2-18_Acar retrotransposon, or a CR1-1_Acar retrotransposon;
wherein the at least one heterologous polypeptide comprises an RNA/DNA processing polypeptide or domain thereof, an RNA/DNA repair polypeptide or domain thereof, a nucleic acid binding polypeptide or domain thereof, or a nucleosome binding polypeptide or domain thereof, and
wherein the engineered protein exhibits at least one improved integration characteristic, as compared to a retroelement-derived polypeptide not fused to the at least one heterologous polypeptide.

### Claim at position 2

-3. (canceled)

### Claim 4 (depends on 1)

The nucleic acid of claim 1, wherein the at least one heterologous polypeptide comprises an RNA/DNA processing polypeptide or domain thereof.

### Claim 5

(canceled)

### Claim 6 (depends on 4)

The nucleic acid of claim 4, wherein the RNA/DNA processing polypeptide is a Rad51 polypeptide, an RNAseH domain, or a DNA polymerase.

### Claim 7

(canceled)

### Claim 8 (depends on 1)

The nucleic acid of claim 1, wherein the at least one heterologous polypeptide comprises an RNA/DNA repair polypeptide or domain thereof.

### Claim 9

(canceled)

### Claim 10 (depends on 8)

The nucleic acid of claim 8, wherein the RNA/DNA repair polypeptide is a CtIP-derived polypeptide, a RecT-derived polypeptide, an HSV-1 alkaline nuclease-derived polypeptide, a BRCA2-derived polypeptide, a DSS1-derived polypeptide, a nanog-derived polypeptide, an NBN-derived polypeptide, a RAD17-derived polypeptide, an ANKRD28-derived polypeptide, a PCNA interaction motif polypeptide, a MDC1-derived polypeptide, a MSH4-derived polypeptide, a SCML1-derived polypeptide, a CDKN2A-derived polypeptide, a 53BP1 inhibitor, or a p53 inhibitor.

### Claim at position 10

-21. (canceled)

### Claim 22 (depends on 1)

The nucleic acid of claim 1, wherein the at least one heterologous polypeptide comprises a nucleic acid binding polypeptide or domain thereof.

### Claim 23 (depends on 22)

The nucleic acid of claim 22, wherein the nucleic acid binding polypeptide comprises a non-sequence specific DNA binding polypeptide or domain thereof.

### Claim 24 (depends on 23)

The nucleic acid of claim 23, wherein the non-sequence specific DNA binding polypeptide comprises a Sto7d DNA binding domain having an amino acid sequence that is at least 70% identical to the sequence as set forth in SEQ ID NO: 26, or an Sso7d DNA binding domain having an amino acid sequence that is at least 70% identical to the sequence as set forth in SEQ ID NO: 377.

### Claim at position 14

-26. (canceled)

### Claim 27 (depends on 1)

The nucleic acid of claim 1, wherein at least one heterologous polypeptide comprises a nucleosome binding polypeptide or domain thereof.

### Claim 28 (depends on 27)

The nucleic acid of claim 27, wherein the nucleosome binding polypeptide comprises;
(a) an HMGN1 polypeptide having an amino acid sequence that is at least 70% identical to the sequence as set forth in SEQ ID NO:23;
(b) an HMGB1 polypeptide having an amino acid sequence that is at least 70% identical to the sequence as set forth in SEQ ID NO:24; or
(c) an StkC DNA binding domain having an amino acid sequence that is at least 70% identical to the sequence as set forth in SEQ ID NO:402.

### Claim at position 17

-30. (canceled)

### Claim 31 (depends on 1)

The nucleic acid of claim 1, wherein the engineered protein comprises the at least one heterologous polypeptide fused to the N-terminus of the retroelement-derived polypeptide, to the C-terminus of the retroelement-derived polypeptide and/or internally within the retroelement-derived polypeptide.

### Claim at position 19

-35. (canceled)

### Claim 36 (depends on 1)

The nucleic acid of claim 1, wherein engineered protein comprises a plurality of heterologous polypeptides.

### Claim at position 21

-54. (canceled)

### Claim 55 (depends on 1)

The nucleic acid of claim 1, wherein the retroelement-derived polypeptide is a retroelement-derived polypeptide variant comprising an amino acid substitution, an amino acid deletion, an amino acid truncation, or a combination thereof, when compared to a wild type retroelement-derived polypeptide.

### Claim 56 (depends on 1)

The nucleic acid of claim 1, wherein the retroelement-derived polypeptide comprises a reverse transcriptase domain, an endonuclease domain, an integrase domain, and/or an RNA binding domain.

### Claim at position 24

-126. (canceled)

### Claim 127 (depends on 1)

The nucleic acid of claim 1 comprising a codon optimized sequence, wherein the codon optimized sequence is optimized for expression in human cells.

### Claim at position 26

-130. (canceled)

### Claim 131 (depends on 1)

An engineered protein encoded by the nucleic acid of claim 1.

### Claim 132 (depends on 1)

A composition comprising:
a) the first nucleic acid of claim 1; and
b) a second nucleic acid comprising a polynucleotide encoding a gene of interest.

### Claim 133 (depends on 132)

The composition of claim 132, wherein the first and second nucleic acids are separate DNA molecules or separate RNA molecules, or wherein one of the first and second nucleic acids is a DNA molecule and one of the first and second nucleic acids is an RNA molecule.

### Claim at position 30

-160. (canceled)

### Claim 161 (depends on 132)

The composition of claim 132, wherein the first and second nucleic acids are comprised within a plurality of LNP particles.

### Claim 162 (depends on 1)

A method of modifying a polynucleotide, comprising contacting a polynucleotide with the nucleic acid of claim 1.

### Claim 163

(canceled)

### Claim 164 (depends on 1)

A method of treating a subject in need thereof comprising administering to the subject the nucleic acid of claim 1.

### Claim at position 35

-166. (canceled)
